Novo Nordisk AS wants to acquire Belgian Nanobody developer Ablynx NV for €2.6bn to access its late-stage blood disorder drug caplacizumab, but Ablynx has rejected two offers from the diabetes giant because the figures "fundamentally undervalue Ablynx and its strong prospects for continued growth."
While a takeover would make sense for Novo Nordisk, which desperately needs to boost its pipeline outside of diabetes and...








